Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 10,355 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Congenital, Hereditary, and Neonatal Diseases and Abnormalities Clear all

Conditions: Respiratory Distress Syndrome, Newborn
Interventions: Surfactant; Drug
Lead sponsor: Sood, Beena G., MD, MS; Individual
Eligibility: Up to 24 Hours
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Cervical Spine Fusion
Interventions: Anterior Cervical Discectomy & Fusion, Application of ADAM mechanoacoustic skin sensor; Procedure · Device
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 88 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Retinopathy of Prematurity
Interventions: RetCam retinal imaging used for routine care; Procedure
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 32 Weeks to 40 Weeks
Enrollment: 244 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 5
States / cities: Baltimore, Maryland • Oklahoma City, Oklahoma • Philadelphia, Pennsylvania + 2 more

Conditions: Heart Defects, Congenital, Pediatrics
Interventions: CHAMP App; Device
Lead sponsor: Lori Erickson; Other
Eligibility: Up to 18 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 9
States / cities: Washington D.C., District of Columbia • Miami, Florida • New Orleans, Louisiana + 6 more

Conditions: Muscular Dystrophies, Limb-Girdle (GENETICALLY CONFIRMED)
Interventions: Not listed
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 6 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Charlotte, North Carolina

Conditions: Atopic Dermatitis
Interventions: IMVAMUNE; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 632 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 15
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more

Conditions: Congenital Myasthenic Syndrome
Interventions: Not listed
Lead sponsor: argenx; Industry
Eligibility: 2 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 7
States / cities: Sacramento, California • Chicago, Illinois • O'Fallon, Illinois + 4 more

Conditions: Sickle Cell Disease
Interventions: Patient Navigator, Recruitment into Specialty Care; Behavioral
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 15 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hemophilia A or B
Interventions: Not listed
Lead sponsor: Sanofi; Industry
Eligibility: 12 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Atopic Dermatitis
Interventions: Baricitinib, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 60
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 52 more

Conditions: DOK 8, STAT1, GATA2, Immunodeficiency, STAT3
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 1 Day to 101 Years
Enrollment: 5,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1995
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Marfan Syndrome, Marfan Related Disorders, Control Subjects
Interventions: Not listed
Lead sponsor: Shriners Hospitals for Children; Other
Eligibility: 4 Years to 26 Years
Enrollment: 336 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 5
States / cities: Chicago, Illinois • Omaha, Nebraska • Portland, Oregon + 1 more

Conditions: Sickle Cell Disease
Interventions: Placebo, Zoledronic Acid; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Pectus Excavatum
Interventions: Epidural, PCA; Other
Lead sponsor: Children's Mercy Hospital Kansas City; Other
Eligibility: 12 Years to 17 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 1
States / cities: Kansas City, Missouri

Conditions: Duchenne Muscular Dystrophy
Interventions: Prednisolone; Drug
Lead sponsor: Anne M. Connolly; Other
Eligibility: 1 Month to 30 Months · Male only
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 4
States / cities: Chicago, Illinois • Cincinnati, Ohio • Columbus, Ohio + 1 more

Conditions: Fragile X Syndrome
Interventions: Working Memory Training; Other
Lead sponsor: University of California, Davis; Other
Eligibility: 8 Years to 18 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Myasthenic Syndromes, Congenital
Interventions: amifampridine phosphate, Placebo; Drug
Lead sponsor: Catalyst Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Boston, Massachusetts + 1 more

Conditions: Neuroendocrine Tumors, Von Hippel-Lindau Syndrome, Hippel-Lindau Disease
Interventions: 68Gallium DOTATATE, Radio-guided surgery; Drug · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 10 Years to 99 Years
Enrollment: 341 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pulmonary Arterial Hypertension, Congenital Heart Disease, Eisenmenger's Syndrome
Interventions: Iloprost; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Primary Ciliary Dyskinesia
Interventions: Beet-it Juice; Dietary Supplement
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 4 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Atopic Dermatitis
Interventions: PR022; Drug
Lead sponsor: Realm Therapeutics, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Lynch Syndrome, Endometrial Cancer, Endometrial Hyperplasia, Mismatch Repair Deficiency, Microsatellite Instability
Interventions: Immunohistochemical staining; Diagnostic Test
Lead sponsor: WellSpan Health; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 91 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: York, Pennsylvania

Conditions: Diabetes Mellitus Type 1, Diabetes Mellitus Type 2
Interventions: Sitagliptin (Januvia); Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bone Marrow Failure Syndrome, Severe Aplastic Anemia, Severe Congenital Neutropenia, Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Schwachman Diamond Syndrome, Primary Immunodeficiency Syndromes, Acquired Immunodeficiency Syndromes, Histiocytic Syndrome, Familial Hemophagocytic Lymphocytosis, Lymphohistiocytosis, Macrophage Activation Syndrome, Langerhans Cell Histiocytosis (LCH), Hemoglobinopathies, Sickle Cell Disease, Sickle Cell-beta-thalassemia
Interventions: CD34 Stem Cell Selection Therapy; Biological
Lead sponsor: Diane George; Other
Eligibility: Up to 40 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2030
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Aerosolized Surfactant in Neonatal RDS

Measuring Dysphagia After ACDF Surgery Through A Novel Wearable Sensor

Telemedicine Approaches to Evaluating Acute-Phase ROP eROP Implementation Project

CHAMP App Cardiac Study and Repository

Limb Girdle Muscular Dystrophy (LGMD) Natural History

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7, MUSK, AGRN, or LRP4

Enhancing Use of Hydroxyurea In Sickle Cell Disease Using Patient Navigators

A Study to Describe Patient REal-world FitusiRan ExpeRience

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

Genetic Analysis of Immune Disorders

Development of a Blood Test for Marfan Syndrome

Phase 1 Study of Zoledronic Acid in Sickle Cell Disease

Prospective Trial: Pain Management After Pectus Excavatum Repair, Epidural Versus PCA

Once Weekly Infant Corticosteroid Trial for DMD

Cognitive Training for Fragile X Syndrome

Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes

Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors

Iloprost for the Treatment of Pulmonary Hypertension in Adults With Congenital Heart Disease

The Effect of a Dietary Supplement Rich in Nitric Oxide in Patients Diagnosed With Primary Ciliary Dyskinesia.

Efficacy and Safety of PR022 Topical Gel to Treat Mild-to-Moderate Atopic Dermatitis

Frequency of Endometrial Cancer Precursors Associated with Lynch Syndrome

Assessment of the Effects of a DPP-4 Inhibitor (Sitagliptin) Januvia on Immune Function in Healthy Individuals

CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation